|
|
Congress Alerts
|
Clinical Spotlight from the 2011 Annual Multidisciplinary Cancer Meeting in Stockholm
|
|
prIME Oncology invites you to view exciting news released from the 2011 Annual Multidisciplinary Cancer Meeting in Stockholm, Sweden.
|
|
|
 |
|
28 September 2011
This expert interview with Fabrice André, MD, PhD, from the Institut Gustave Roussy
Villejuif, France, and José Baselga, MD, PhD, from the Massachusetts General Hospital, Boston, Massachusetts, United States, along with an eNewsflash and downloadable slides, covers the topic of breast cancer focusing on the following data release:
Abstract #LBA9: Everolimus in combination with exemestane for postmenopausal women with advanced breast cancer who are refractory to letrozole or anastrozole: Results of the BOLERO-2 phase III trial
Learning Objectives:
Upon completion of this educational activity, participants should be able to:
- Summarize the most recent clinical trial data regarding novel therapeutic options for the management of breast cancer, and outline best strategies for the integration of these therapies into clinical practice
- Discuss the role of novel targeted agents in overcoming resistance to endocrine therapy in patients with metastatic breast cancer
View expert discussion and access the downloadable slides and eNewsflash
|
 |
|
27 September 2011
This expert interview with Eric Van Cutsem, MD, PhD, from the University Hospital Gasthuisberg,
Leuven, Belgium, and, Josep Tabernero, MD, from the Vall d'Hebron University Hospital, Barcelona, Spain, along with an eNewsflash and downloadable slides, covers the topic of metastatic colorectal cancer focusing on the following data release:
Abstract #LBA6: Results from VELOUR, a phase III study of aflibercept (A) versus placebo (pbo) in combination with FOLFIRI for the treatment of patients (pt) with previously treated metastatic colorectal cancer (MCRC)
Learning Objectives:
Upon completion of this educational activity, participants should be able to:
- Evaluate emerging clinical trial data pertaining to colorectal cancer and how this data should be incorporated into current standards of care to improve patient outcomes
- Discuss the rationale and utility of novel antiangiogenic agents that may provide superior outcomes for patients with colorectal cancer compared to current standards of care
View expert discussion and access the downloadable slides and eNewsflash
|
|
|
|
|
|
|
